Altre lingue Takeda Pharmaceutical Company Limited Börse Stuttgart

Azioni

TKD

JP3463000004

Mercato chiuso - Börse Stuttgart Altri mercati azionari 08:07:14 20/06/2024			Variaz. 5gg	Var. 1 gen.
23,45 ^EUR	-1,18%		-2,98%	-8,09%

18/06	Takeda Pharmaceutical afferma che i risultati dello studio di fase 3 supportano l'uso di Hyqvia come trattamento di mantenimento per la CIDP	MT
18/06	Takeda annuncia i dati dello studio clinico di Fase 3 ADVANCE-CIDP 3 di HYQVIA nei pazienti con polineuropatia demielinizzante infiammatoria cronica al Meeting annuale PNS	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Takeda présente au congrès annuel de la PNS des données à long terme de l’essai clinique ADVANCE-CIDP 3 de Phase 3 portant sur l’administration de HYQVIA® à des patients atteints de polyradiculonévrite inflammatoire démyélinisante chronique (PIDC)	19/06
Takeda presenta datos de largo plazo del ensayo clínico de fase 3 ADVANCE-CIDP 3 de HYQVIA® en pacientes con polineuropatía desmielinizante inflamatoria crónica (PDIC) en la Reunión Anual de la PNS	19/06
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	19/06
Takeda präsentiert Langzeitdaten der klinischen Phase-3-Studie ADVANCE-CIDP 3 mit HYQVIA® bei Patienten mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP) auf der PNS-Jahrestagung	19/06
Ovid Therapeutics Reports on Takeda s Announcement of Phase 3 Topline Study Results for Soticlestat	18/06
Takeda Pharmaceutical Says Results of Phase 3 Trial Support Use of Hyqvia as Maintenance Treatment for CIDP	18/06
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting	18/06
Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting	18/06
Takeda's Soticlestat Shows Promising Secondary Outcomes in Phase 3 Studies for Dravet and Lennox-Gastaut Syndromes	18/06
Ovid Therapeutics Shares Slide Premarket After Takeda's Soticlestat Setback	17/06
Sector Update: Health Care Stocks Decline Premarket Monday	17/06
Investors Look for Fresh Impetus Ahead of Holiday Break, Stifling US Equity Futures Pre-Bell	17/06
Ovid Seeks Distance From Epilepsy Drug After Takeda Reports Phase 3 Endpoints Missed -- Pre-Bell Shares Fall	17/06
Takeda Says Phase 3 Soticlestat Trials in Dravet, Lennox-Gastaut Syndromes Missed Primary Endpoints	17/06
Takeda's Soticlestat Misses Goals in Phase 3 Epilepsy Studies	17/06
Takeda's seizure drug fails to meet main goal in late-stage studies	17/06
Takeda Pharmaceutical Company Limited Announces Topline Data from its Phase 3 SKYLINE and SKYWAY Studies Evaluating Soticlestat for the Treatment of Dravet Syndrome and Lennox-Gastaut Syndrome	17/06
Takeda Pharmaceutical : Announces Phase 3 Topline Results for Soticlestat (TAK 935) in Patients with Dravet Syndrome and Lennox Gastaut Syndrome Form 6 K	17/06
Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome	17/06
Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome	17/06

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Takeda Pharmaceutical Company Limited Börse Stuttgart

Azioni

TKD

JP3463000004

Altre lingue

Filtri